Hematopoiesis and Hematologic Malignancy

Angelo Cardoso, M.D., Ph.D.
Angelo Cardoso, M.D., Ph.D., research professor and director of the Laboratory for Cellular Medicine in the Center for Gene Therapy, received his M.D. and Ph.D. from Porto University and University of Paris XI Medical School, respectively. He studies how oncogenic signals interact with micro-environmental cues in an attempt to develop novel inhibitors targeting high-risk and refractory relapsed pediatric acute lymphoblastic leukemia.
 
Nadia Carlesso, M.D., Ph.D. 
Nadia Carlesso, M.D., Ph.D., professor and chair of the Department of Developmental and Stem Cell Biology, received her Ph.D. from the University of Genoa and Dana-Farber Cancer Institute. She is investigating the role of the tumor microenvironment in leukemia progression to identify novel therapeutic approaches to defeat leukemia drug resistance and relapse. 
 
Wing-Chun (John) Chan, M.D.
Wing-Chun (John) Chan, M.D., the Dr. Norman & Melinda Payson Professor in Hematologic Cancer, received his M.D. from the University of Hong Kong. His research focuses on using genomics approaches to explore the molecular pathogenesis and classification of lymphoma. He has identified molecular signature to improve diagnosis, outcome prediction and treatment response for lymphoma patients.
 
Jianjun Chen, Ph.D. 
Jianjun Chen, Ph.D., the Simms/Mann Family Foundation Chair in Systems Biology, professor and chair of the Department of Systems Biology, received his Ph.D. from Chinese Academy of Sciences. His team focuses on basic and translational research associated with RNA/DNA epigenetics, especially N6 methyl-adenosine (m6A) RNA modification and TET protein mediated DNA methylation, in the development and drug response of cancers. 
 
Wenyong Chen, Ph.D. 
Wenyong Chen, Ph.D., associate professor in the Department of Cancer Biology, received his Ph.D. from the University of Alabama at Birmingham. His laboratory is interested in understanding epigenetic regulation of hematopoietic stem cell aging, leukemia development and drug resistance in leukemia stem cells.
 
Stephen Forman, M.D. 
Stephen Forman, M.D., professor in Department of Hematology & Hematopoietic Cell Transplantation and director of the Hematologic Malignancies Research Institute, received his M.D. from the University of Southern California. His research is focused on developing genetically engineered CAR T cells to promote adoptive immunotherapy in the treatment of a wide range of cancers.  
 
Zhaohui Gu, Ph.D., assistant professor in the Department of Computational and Quantitative Medicine and the Department of Systems Biology, received his Ph.D. from Shanghai Jiao Tong University. His research has focused on leukemia genomics and led to productive publications including Nature, Nature Genetics and Nature Communications, PNAS, etc.
 
Nora Heisterkamp, Ph.D. 
Nora Heisterkamp, Ph.D., professor in the Department of Systems Biology, received her Ph.D. from University of Rotterdam. Her team focuses on defining the molecular mechanism by which nonleukemia cells stimulate precursor B-lineage acute lymphoblastic leukemia cell growth and provide chemotherapeutic resistance via direct cell contact. 
 
Ya-Huei Kuo, Ph.D. 
Ya-Huei Kuo, Ph.D., associate professor in the Department of Hematologic Malignancies Translational Science, received her Ph.D. from the University of Connecticut. Her research is directed at understanding the molecular mechanisms involved in the development of acute myeloid leukemia to facilitate improved cancer treatments.
 
Larry W. Kwak, M.D., Ph.D. 
Larry W. Kwak, M.D., Ph.D., the Dr. Michael Friedman Professor in Translational Medicine, professor in Department of Hematology and Hematopoietic Cell Transplantation, received his M.D. and Ph.D. from Northwestern University. His laboratory focuses on studying novel immunotherapies to treat mantle cell lymphoma, a particularly aggressive type of lymphoma with a poor survival record.
 
Ling Li, Ph.D. 
Ling Li, Ph.D., associate professor in the Department of Hematologic Malignancies Translational Science, received his Ph.D. from Zhejiang University. His laboratory focuses on determining the role of SIRT1 and p53 in regulating leukemia stem cell growth, with the ultimate goal of creating novel therapeutics for leukemia.
 
Guido Marcucci, M.D. 
Guido Marcucci, M.D., professor and chair of the Department of Hematologic Malignancies Translational Science, received his M.D. from Catholic University of the Sacred Heart. He is intensely interested in the pathogenesis, the maintenance and treatment of both chronic and acute myelogenous leukemia.
 
Christiane Querfeld, M.D., Ph.D.  
Christiane Querfeld, M.D., Ph.D., associate professor in the Division of Dermatology and Division of Anatomic Pathology, received her M.D. and Ph.D. from the University of Cologne and University of Heidelberg, respectively. Her research focuses on understanding the biology of cutaneous lymphomas and developing therapies for this class of cancer.
 
Steven Rosen, M.D. 
Steven Rosen, M.D., the Irell & Manella Cancer Center Director's Distinguished Chair, provost, chief scientific officer, director of Beckman Research Institute of City of Hope and the comprehensive cancer center, and professor in the Department of Hematology & Hematopoietic Cell Transplantation, received his M.D. from Northwestern University. His team is developing novel therapies for hematologic malignancy by targeting ATP synthase, dihydroorotate dehydrogenase, histone deacetylase and de-ubiquinase. 
 
Srividya Swaminathan, Ph.D., assistant professor in the Department of Systems Biology, received her Ph.D. from the University of Southern California. Her lab focuses on identifying noncytotoxic and targeted immunotherapies for treating oncogene addicted B and T cell malignancies driven by genomic rearrangements.
 
Leo Wang, M.D., Ph.D. 
Leo Wang, M.D., Ph.D., assistant clinical professor in the Department of Immuno-Oncology and Department of Pediatrics, received his M.D. and Ph.D. from the University of Chicago. The lab uses protein-focused techniques to identify non-genetic determinants of functional differences in benign and malignant blood cells, and to understand CAR T cell signaling and function. The lab also performs CAR T cell clinical trials in pediatric brain tumor patients.
 
Lili Wang, M.D., Ph.D.
Lili Wang, M.D., Ph.D., associate professor in the Department of Systems Biology, received her M.D. from China Medical University and her Ph.D. from Tokai University. Her research involves understanding how somatic mutations contribute to the development of chronic lymphocytic leukemia.
 
Sophia Wang, Ph.D. 
Sophia Wang, Ph.D., professor in the Department of Computation and Quantitative Medicine, received her Ph.D. from Johns Hopkins Bloomberg School of Public Health. Her research is focused on the etiology of hematopoietic malignancies and the role that immune genes, which play a role in inflammation, impact lymphoma etiology and survival.
 
Xiuli Wang, Ph.D., research professor in the Department of Hematology & Hematopoietic Cell Transplantation, received her Ph.D. from the University of Oslo. Her work focuses on preclinical and translational research on CAR T cell therapy for hematological malignancy and HIV.
 
Defu Zeng, Ph.D. 
Defu Zeng, Ph.D., professor in the Department of Immunology & Theranostics and Department of Diabetes Complications & Metabolism, received his Ph.D. from Fujian Medical University. His laboratory focuses on understanding the pathogenesis of graft-versus-host disease, which is a major obstacle in allogeneic hematopoietic cell transplantation for the treatment of hematological malignancies.